Femasys (FEMY)

• Market cap: $33.7M
• 1 day: 14.81%
• 5 days: 11.71%
• 1 month: -22.50%
• 3 months: 11.71%
• 6 months: 1.64%
• Year to date: 12.73%
• 1 year: -4.62%
• 5 years: -89.67%
• 10 years: -89.67%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Employees: 71

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

43% more capital invested

Capital invested by funds: $1.8M [Q3] → $2.57M (+$769K) [Q4]

8% more funds holding

Funds holding: 26 [Q3] → 28 (+2) [Q4]

2.9% more ownership

Funds ownership: 7.31% [Q3] → 10.21% (+2.9%) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 1,110% upside
• Avg. target: $15 1,110% upside
• High target: $15 1,110% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 11% 1-year accuracy 18 / 159 met price target

1,110% upside $15

Buy Reiterated

28 Mar 2025